Calciphylaxis is a disease of significant morbidity and mortality, predominantly affecting dialysis patients. The term 'calciphylaxis' was coined by Seyle et al. in 1961 to describe calcium deposition in the skin and subcutaneous soft tissue of uremic rats in response to 'triggers' (e.g. trauma, metallic salts) after exposure to 'sensitizing agents' (e.g. vitamin D and parathyroid hormone). In humans, calciphylaxis, however, is not a disorder of induced hypersensitivity. Instead, it is a disorder of cutaneous microvascular occlusion caused by thrombosis and calcification. Progressive, excruciatingly painful, non-healing wounds develop in these patients, pre-disposing them to high risk of sepsis and death. Calciphylaxis has no approved therapies. Increased awareness and research in this field have facilitated identification of risk factors and causation pathways. Development of therapeutic options and wound care management, however, are still at a nascent stage. Certain therapies have shown a promise that needs evaluation in prospective clinical trials. It is hoped that ongoing research will help us better understand the pathogenesis of this complex disease and develop efficacious treatment options. In this review, we outline the components involved in calciphylaxis diagnosis and treatment.
Introduction
Calciphylaxis is a rare, devastating disorder causing excruciatingly painful ischemic skin lesions due to microvascular calcification and thrombosis in the dermis and subcutaneous adipose tissue. 1, 2 Calciphylaxis is recognized worldwide as a disease of significant morbidity and mortality. The disease is also referred to as calcific uremic arteriolopathy (CUA) as most cases are described in patients with the uremic milieu of end-stage renal disease (ESRD). Non-ESRD patients, however, may constitute up to 20% of the calciphylaxis population. 2, 3 Prognosis is typically poor, with mortality rates many folds higher in hemodialysis patients who develop calciphylaxis compared with the average hemodialysis population. Survival in non-ESRD patients (40-50% 1-year mortality rate) is better than in ESRD patients (50-80% 1-year mortality rate). 2, 4, 5 Infection of the ulcerated wounds leading to sepsis is a common cause of death in patients with calciphylaxis. In a retrospective study of 101 calciphylaxis patients (ESRD and non-ESRD), the average age was 60 years, 80% were females and 70% were obese. 2 Thrombophilia and vitamin K antagonist use were present in 80% and 60% of patients, respectively. 2 Data obtained from the German Calciphylaxis Registry and a US study of calciphylaxis in the dialysis population show a similar predilection for female patients and for patients with vitamin K antagonist use. 3, 4 Vitamin K is an essential co-factor for synthesis of carboxylated matrix Gla protein (cMGP), a potent inhibitor of vascular calcification. A case-control study of 20 patients with calciphylaxis and 20 matched controls showed that patients with calciphylaxis have reduced relative cMGP concentration and a high prevalence of vitamin K deficiency relative to controls. 6 In a study by Chen et al. 7 , skin biopsies from ESRD patients with calciphylaxis (n ¼ 57) were compared with those from ESRD patients without calciphylaxis (n ¼ 26). Histopathology of calciphylaxis patients was significantly more likely to show calcification of cutaneous vessels and diffuse thrombi. A new observation in this study was the frequent finding of dermal angioplasia, indicative of low-grade ischemia, in tissue samples from calciphylaxis patients.
In this review, we provide an update on the diagnosis and treatment of calciphylaxis. Investigating and understanding calciphylaxis is of specific interest also for the more general arteriosclerosis associated with aging, chronic kidney disease and diabetes, since calciphylaxis might serve as a high-speed template for this widespread vascular calcification disorder.
Diagnosis
Understanding of clinical features is essential for the early diagnosis of calciphylaxis. Intense pain at the cutaneous lesion site is typical. Areas most commonly affected include those with the greatest adiposity, (e.g. thighs, abdomen and buttocks). The lesions manifest as subcutaneous indurated plaques, and nodules with a pattern of livedo racemosa indicating a vascular event ( Figure 1 ). 8 Early lesions may be solitary or multifocal.
Progression of the induration to the surface of the skin causes initial skin blisters followed by large ulcerations characterized by a thick adherent eschar ( Figure 2 ). There is a high likelihood for calciphylaxis in a dialysis patient presenting with such skin lesions. Concomitant risk factors such as warfarin use further increases the clinical diagnostic suspicion. Thrombophilia, both inherited and acquired, are common in calciphylaxis patients. 9 Coagulation profile should be assessed in patients with calciphylaxis. Findings on imaging studies such as technetium bone scans, CT scans and X-rays can support the diagnosis of calciphylaxis. However, further prospective studies are required before they can be recommended as diagnostic modalities.
Management
Treatment of calciphylaxis requires a multi-disciplinary approach involving nephrology, dermatology, plastic surgery, wound care, pain management and palliative care. A summary of treatments described in the clinical management of patients with calciphylaxis is provided in Table 1 .
Treatments can be broadly categorized into: (i) those targeting vascular calcification, (ii) those targeting thrombosis, (iii) wound care and (iv) pain management.
Treatments targeting vascular calcification
Management of mineral metabolism Derangements in parameters of mineral bone metabolism (calcium, phosphorous, parathyroid hormone) are frequent in dialysis-dependent patients who develop calciphylaxis. These abnormalities need corrections with a goal to maintain normal serum calcium, normal serum phosphorous and serum parathyroid hormone level typically in the range of 150-300 ng/ml. Vitamin D analogues, calcium supplements and calcium-based phosphorous binders should be avoided to avoid positive calcium load and potential exacerbation of soft tissue and vascular calcification. Instead, non-calcium based phosphorous binders are suggested to treat refractory hyperphosphatemia despite dietary adherence to low phosphorous foods.
In patients with severely elevated parathyroid hormone levels, calcimimetics should be considered. In a randomized trial comparing outcomes of cinacalcet with placebo in hemodialysis patients, the rate of calciphylaxis was lower in the treatment arm (hazard ratio [HR]: 0.31; 95% confidence interval [CI]: 0.13-0.79) though the event rates in both arms were low (<1%). 13 Prospective studies are required to examine the role of calcimimetics for reducing the risk of calciphylaxis and for modifying outcomes in patients with calciphylaxis. Surgical parathyroidectomy is suggested for patients' refractory to calcimimetic therapy. 2, 5 Perioperative mortality after parathyroidectomy in ESRD patients 14 and the risk of hungry bone syndrome requiring calcium supplementation make parathyroidectomy less favorable as the first line treatment. A typical ESRD patient undergoes hemodialysis for 4 h three times a week. Intensification of hemodialysis (more frequent or longer sessions) and transition from peritoneal dialysis to hemodialysis may be required for patients with uncontrolled bone and mineral abnormalities. Calciphylaxis patients should be dialyzed against a low calcium bath to avoid hypercalcemia. The calcium level in the dialysate typically mimics the ionized or free calcium level in the plasma (5 mg/dl). Dialysate solutions containing 2.5-3 mg/dl of calcium remove more calcium from the patient through diffusion.
Sodium thiosulfate
Sodium thiosulfate was first reported to be effective in calciphylaxis in 2004. 15 Potential effectiveness of sodium thiosulfate, an agent with calcium chelating properties, may also be related to its anti-oxidative and vasodilatory properties. An in vitro study showed that sodium thiosulfate induced a dose dependent reduction in adipocyte calcification and adipocyte-induced vascular smooth muscle calcification. 16 Peng et al. 17 recently reported a systematic review and meta-analysis that included 83 papers including 36 case reports and nine multi-case reports. In this meta-analysis, sodium thiosulfate led to improvement or resolution of calciphylaxis lesions in 70% of patients. However, none of the included studies had a comparison arm and all were retrospective. In a separate cohort study where a comparison arm was available, sodium thiosulfate did not associate with improved 6-month mortality (HR: 1.01, 95% CI: 0.54-1.90). 2 Similarly, in patients with calciphylaxis and normal renal function, sodium thiosulfate did not improve survival. 18 Despite limitations of published data, sodium thiosulfate is frequently considered in the treatment of calciphylaxis. It is typically administered intravenously in the last 30-60 min of hemodialysis. Its side effects may include nausea, metabolic acidosis, volume overload and hypocalcemia.
A clinical trial is underway to test the safety and efficacy of sodium thiosulfate in the treatment of calciphylaxis [NCT03150420].
Bisphosphonates
Bisphosphonates are analogues of pyrophosphate, which is a potent inhibitor of calcium hydroxyapatite formation. In addition, they have anti-inflammatory effects that may play a role in decreasing vascular smooth muscle calcification. Torregrosa et al. 19 compared patients who received standard care with patients who received bisphosphonates in addition to standard of care. All patients in the bisphosphonates (n ¼ 11) cohort demonstrated significant improvement in pain and severity of skin lesions. However, these data need evaluation in controlled studies. 
Other treatments for calcification

Treatments targeting vascular thrombosis
In calciphylaxis, like myocardial infarction, thrombosis of the arterioles and ischemia of the panniculus and dermis leads to the necrotic subcutaneous nodules, which then proceed to ulcerate. High rates of thrombophilia in patients with calciphylaxis and the frequent presence of mural thrombus on histological specimens, supports investigating the role of antithrombotic treatment in the management of calciphylaxis. In a study of 15 patients who received a course of tissue plasminogen activator (TPA) (10 mg intravenous daily for 10-14 days), it was noted that patients responded well while in the hospital but regression occurred after discharge probably due to resumption of warfarin and minimal wound care. 20 TPA is rarely used now because of concerns over bleeding. Currently, non-vitamin K oral anti-coagulants are suggested as an alternative to warfarin for anti-coagulation in patients with calciphylaxis based on retrospective data that support maintaining anticoagulation particularly for those with thrombophilic conditions. [21] [22] [23] However, the safety and efficacy of novel anticoagulants in dialysis patients lacks confirmation in prospective studies and these agents are not approved for dialysis patients by all regulatory agencies.
Wound care
There is no consensus agreement about wound care in the management of calciphylaxis. The key is to ensure that infection is prevented, and the wound healing is facilitated. Sophisticated wound care with frequent dressing changes is suggested. Debridement is indicated for wounds that are infected such as those with significant drainage or pus formation. Dry wounds are best managed non-surgically. In a retrospective study of 101 patients with calciphylaxis, 29 patients underwent surgical debridement. Lack of surgical debridement was associated with significantly higher overall mortality (HR: 1.99; 95% CI: 1.15-3.41).
2 However, the patients were not matched for comorbidities or severity of illness and possibly there may have been selection bias. Hyperbaric oxygen therapy is an adjunctive treatment to help restore oxygenation and healing of tissues. An et al. reported outcomes in 34 calciphylaxis patients who had failed conventional therapies and were referred to their center for hyperbaric oxygen therapy as a last resort. Improvement in wound healing was seen in approximately 60% of patients, with complete resolution of wounds in half of them and there was a survival benefit in responders. 24 However, selection bias significantly limits conclusive interpretation of results. Furthermore, although side effects such as barotrauma and oxygen toxicity seizures are rare, access, cost and interference to scheduling from other treatments such as dialysis are major barriers. Hyperbaric oxygen therapy could be a useful adjunct therapy in calciphylaxis patients with ulcerated lesions involving areas such as lower legs. A typical therapy session lasts approximately 30-45 min and patients require multiple sessions, making it challenging to implement hyperbaric oxygen earlier in the therapy plan rather than at an advanced stage in calciphylaxis patients. Injudicious use of antibiotics should be avoided in the absence of clear signs of infection. Agents that delay wound healing such as mTOR inhibitors should be switched to an alternate agent when possible. For patients receiving subcutaneous injections of medications (e.g. insulin for diabetes treatment), injection sites should be rotated to minimize recurrent skin trauma. A formal nutrition evaluation with a view to avoiding malnutrition is important for optimal wound healing.
Pain management
Excruciating pain is an overwhelming theme in calciphylaxis patients and is the main factor affecting quality of life. The mechanism of pain in calciphylaxis is poorly understood but it was noted that patients that were treated with TPA generally experienced pain relief after 3-4 days of TPA infusion suggesting that the pain may be related to ischemia 20 ; but there may be a neuropathic component as well. 1 Patients require high doses of opioids and pain control remains poor despite that in many patients. Opioids tend to accumulate in renal failure and even at lower doses are associated with adverse outcomes including altered mental status. 25 Therefore, a careful selection of opioids is warranted. Hydromorphone, methadone and fentanyl are preferred over morphine, tramadol and oxycodone. The high risk of opioid overdose or toxicity in these patients necessitates alternative analgesic approaches. Neuropathic agents such as gabapentin, ketamine and benzodiazepine have been used with varying success. Regional anesthesia in the form of a lumbar sympathetic block has been reported to treat the intense refractory pain of calciphylaxis. 26 Access to pain specialists may facilitate improved pain control with reduced side effects in patients with calciphylaxis. Early involvement of palliative care may be beneficial, especially in helping patients cope with the burden of disease and the stigma of living with significant wounds. A recent systematic review of the literature highlighted underutilization of palliative care and patient-reported outcome measures in the published literature. 27 
Conclusion
Calciphylaxis is a rare but devastating disease with poor patient outcomes. Early diagnosis and a multi-disciplinary approach are key components of managing this complex disease. A significant limitation on the development of new therapies has been the rare nature of the disease. A collaborative paradigm that includes industry, academia, clinicians and patients is needed to develop novel diagnostic and therapeutic strategies. A number of clinical trials are ongoing and we encourage recruitment in to these trials to improve our understanding and provide an evidence base for the management of this devastating condition.
